Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kinnate Biopharma Inc (NQ: KNTE ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Kinnate Biopharma Inc < Previous 1 2 3 4 Next > XOMA Corporation Announces Closing of Tender Offer April 03, 2024 Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE) March 25, 2024 From Brodsky & Smith LLC Via GlobeNewswire XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. March 19, 2024 Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – March 19, 2024 From Brodsky & Smith LLC Via GlobeNewswire KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE March 13, 2024 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB) March 13, 2024 From Brodsky & Smith LLC Via GlobeNewswire Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories March 01, 2024 From Kinnate Biopharma; Pierre Fabre Laboratories Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB) February 26, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB) February 20, 2024 From Brodsky & Smith LLC Via GlobeNewswire KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE February 19, 2024 From Kahn Swick & Foti, LLC Via Business Wire Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma February 16, 2024 XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024. Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB) February 16, 2024 From Brodsky & Smith LLC Via GlobeNewswire KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders February 16, 2024 From NEW YORK Via Business Wire Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share February 16, 2024 From Kinnate Biopharma Via GlobeNewswire XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right February 16, 2024 Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio From XOMA Corporation Via GlobeNewswire Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session November 15, 2023 Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session November 15, 2023 Via Benzinga Kinnate Biopharma Inc. (NASDAQ: KNTE) is One of Wednesday Morning’s Most Active Stocks November 15, 2023 Via Investor Brand Network Why is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today? November 15, 2023 Kinnate Biopharma Inc's (NASDAQ: KNTE) board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session November 15, 2023 Via Benzinga Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates November 09, 2023 From Kinnate Biopharma Via GlobeNewswire Analysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuring September 19, 2023 Monday, Kinnate Biopharma Inc (NASDAQ: KNTE) prioritized the exarafenib combination, KIN-8741, and discovery efforts around its Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023 September 19, 2023 Via Benzinga Why Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today? September 19, 2023 Kinnate Biopharma Inc (NASDAQ: KNTE) announced pipeline updates, a reprioritization plan, and workforce restructuring to Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session September 19, 2023 Via Benzinga Dell Technologies To Rally More Than 15%? Here Are 10 Other Analyst Forecasts For Tuesday September 19, 2023 Raymond James increased the price target for Vital Energy, Inc. (NYSE: VTLE) from $54 to $67. Raymond James analyst John Freeman maintained an Outperform rating. Vital Energy shares rose 0.5% to $54.37... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday September 19, 2023 Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning! Via InvestorPlace 12 Health Care Stocks Moving In Monday's After-Market Session September 18, 2023 Via Benzinga Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring September 18, 2023 From Kinnate Biopharma Via GlobeNewswire Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates August 08, 2023 From Kinnate Biopharma Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.